Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Obesity: early-phase trial registry
306 of 1,057 indexed Obesity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3 of 28,707 conditions by registered trial count.
1,057 US clinical trials · 306 currently recruiting · #3 of 28,707 conditions by registered trial count
Obesity: 1,057 US clinical trials tracked, 306 recruiting.
Obesity is the subject of 1,057 registered US clinical trials on ClinicalTrials.gov, 306 of them currently open to new participants. 107 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 48 of these trials.
Enrollment posture brief
Registry condition obesity
OPEN 306 | RECR 29% | LATE 107 | EARLY 196 | RANK #3 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Metastatic Pancreatic Adenocarcinoma (29% recruiting · 38 trials)
Obesity lists 306 open slots (29% of 1,057 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Obesity is recruiting below its size-band peers.
306 of 1,057 indexed trials (28.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Obesity trials is spread across many organizations.
Eli Lilly and Company accounts for 48 of 1,057 trials (4.5%). 314 distinct sponsors appear on at least one study for this condition label.
-
Typical Obesity enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,054 trials that report a genuine target (sentinel values excluded). 555 of those (52.7%) plan for fewer than 100 participants.
-
Obesity research is mostly interventional.
894 interventional and 163 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,057 total, page 7 of 22
Sympathetic Mechanisms in Obesity-Crossover Design
Vanderbilt University Medical Center
NCT05312892
Mechanisms of Semaglutide Therapy in Heart Failure Patients
University Medical Centre Ljubljana
NCT06541509
Diazoxide Suppression Test P&F Study
Columbia University
NCT06606327
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
University of New Mexi
NCT06934642
Feasibility of Semaglutide in Advanced Lung Disease
University of Pennsylvania
NCT05746039
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
University of Colorado, Denver
NCT06414096
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company
NCT05556512
Weight Loss Clinical Decision Support
HealthPartners Institute
NCT05198765
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim
NCT06077864
Partnerships for Reducing Overweight and Obesity with Patient-Centered Strategies 2.0
Brigham and Women's Hospital
NCT05553925
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Amgen
NCT06858839
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
NCT05567796
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
NCT05869903
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company
NCT05803421
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company
NCT05929066
Maternal Obesity, Breast Milk Composition, and Infant Growth
University of Minnesota
NCT03301753
Gut Microbiota, Short Chain Fatty Acids, and Adiposity Across The Epidemiological Transition
Loyola University
NCT03378765
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company
NCT05882045
The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older
University of Illinois at Chicago
NCT05654142
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals
NCT06299098
Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting
Charles Drew University of Medicine and Science
NCT04725058
The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)
Allurion Technologies
NCT05368259
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company
NCT05929079
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company
NCT06914895
Childcare Healthy Beverage Access, Food and Beverage Intake, and Obesity
Stanford University
NCT05112185
Long-term Effectiveness of the Antiobesity Medication Phentermine
Wake Forest University Health Sciences
NCT05176626
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly and Company
NCT06662383
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Boehringer Ingelheim
NCT06066528
A Randomized Trial of Behaviorally Designed Gamification and Social Incentives to Increase Physical Activity Among Overweight and Obese Veterans
VA Office of Research and Development
NCT05554601
Virtual Diabetes Group Visits Across Health Systems
University of Chicago
NCT06094491
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company
NCT06859268
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk A/S
NCT07011667
Rural Engagement in TelemedTeam for Options in Obesity Treatment Solutions
University of Kansas Medical Center
NCT05710510
Elements Vital to Treat Obesity Study
Northwestern University
NCT04708769
Biological Sample Repository for Gastrointestinal Disorders
Pichamol Jirapinyo, MD, MPH
NCT05874726
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
Novo Nordisk A/S
NCT06571383
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company
NCT06962280
Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy
The Miriam Hospital
NCT02917876
TOTAL: A Multisite RCT
VA Office of Research and Development
NCT05346575
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Eli Lilly and Company
NCT06037252
Vida Sana y Completa Obesity and Food Insecurity Study
Stanford University
NCT05211180
Effects of Negative Affect in Individuals With Binge Eating Episodes
University of California, San Diego
NCT03393039
WOOP VA: Promoting Weight Management in Primary Care
VA Office of Research and Development
NCT05014984
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Novo Nordisk A/S
NCT06780449
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
NCT06047548
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Eli Lilly and Company
NCT06373146
Promoting Successful Weight Loss in Primary Care in Louisiana Using Information Technology
Pennington Biomedical Research Center
NCT05523375
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company
NCT06603571
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
Amgen
NCT07226778
Eat Well for Life: A Weight Loss Maintenance Study
The University of Tennessee, Knoxville
NCT01849627
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 95 |
| Phase 2 | 101 |
| Phase 3 | 69 |
| Phase 4 | 38 |
Top Sponsors
Named interventions
Most-linked intervention names on Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Obesity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Obesity page
1,057 registered trials, 306 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 306 Obesity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Obesity trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obesity condition card totals 1,057 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.